This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

2 hours ago 4

Jonathan Ponciano, The Motley Fool

Sat, March 21, 2026 astatine 6:33 PM CDT 4 min read

RTW Investments disclosed a important bargain of Cogent Biosciences (NASDAQ:COGT) successful its February 17, 2026, SEC filing, adding 4,124,755 shares successful a commercialized estimated astatine $115.95 cardinal based connected quarterly mean pricing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, RTW Investments, LP accrued its involvement successful Cogent Biosciences by 4,124,755 shares during the quarter. The estimated transaction value, based connected the mean unadjusted closing terms for the quarter, was $115.95 million. The quarter-end presumption worth roseate by $219.88 million, a fig that includes some trading and marketplace terms changes.

RTW Investments executed a buy, raising its Cogent Biosciences involvement to 2.7% of its 13F reportable AUM.
Top holdings aft the filing:
- NASDAQ:MDGL: $1.16 cardinal (11.6% of AUM)
- NASDAQ:INSM: $842.85 cardinal (8.4% of AUM)
- NASDAQ:PTCT: $588.42 cardinal (5.9% of AUM)
- NASDAQ:ARGX: $566.38 cardinal (5.7% of AUM)
- NASDAQ:PTGX: $441.86 cardinal (4.4% of AUM)
As of Friday, shares of Cogent Biosciences were priced astatine $33.38, up a staggering 360% implicit the past year, compared to a 15% summation for the S&P 500 successful the aforesaid period.

Metric

Value

Price (as of Friday)	$33.38
Market Capitalization	$5.4 billion
Net Income (TTM)	($328.94 million)

Cogent Biosciences develops precision therapies targeting genetically defined diseases, with a pb campaigner (CGT9486) focused connected systemic mastocytosis and gastrointestinal stromal tumors.
The steadfast operates a biotechnology exemplary centered connected research, development, and licensing agreements, with gross imaginable tied to palmy objective advancement and commercialization of proprietary therapies.
It targets healthcare providers, probe institutions, and patients affected by uncommon familial mutations, peculiarly those with KIT-driven cancers and related disorders.

Cogent Biosciences is simply a biotechnology institution specializing successful the improvement of targeted therapies for genetically defined diseases. The institution leverages a focused R&D pipeline and strategical licensing partnerships to beforehand caller treatments for underserved diligent populations. Its competitory borderline lies successful precision medicine approaches aimed astatine mutations with important unmet aesculapian needs.

Based connected size alone, this is what condemnation looks similar erstwhile a communicative shifts from committedness to execution. The stake seems present is little astir chasing a banal that has already surged 360% and much astir leaning into a narrowing model wherever objective occurrence starts translating into commercialized reality.

Cogent is nary longer conscionable different early-stage biotech burning cash. It ended the twelvemonth with astir $900 cardinal connected the equilibrium sheet, capable runway into 2028, portion advancing aggregate regulatory filings tied to its pb drug, including an FDA-accepted exertion with a late-2026 determination timeline.

That matters successful context. This portfolio is built astir high-conviction biotech bets similar Madrigal, Insmed, and Protagonist, wherever ample allocations bespeak a willingness to underwrite objective hazard for outsized outcomes. And against that backdrop, a 2.7% presumption inactive looks measured, not reckless. Now, the existent question is whether upcoming approvals tin validate years of R&D and warrant the stock’s accelerated climb.

Read Entire Article